ZNTL vs. QURE, RLAY, TYRA, ANAB, KURA, CRMD, ABUS, PHAR, IMTX, and ORIC
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include uniQure (QURE), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.
Zentalis Pharmaceuticals vs.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
In the previous week, Zentalis Pharmaceuticals had 5 more articles in the media than uniQure. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 0 mentions for uniQure. Zentalis Pharmaceuticals' average media sentiment score of 0.00 equaled uniQure'saverage media sentiment score.
78.8% of uniQure shares are held by institutional investors. 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Zentalis Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zentalis Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
Zentalis Pharmaceuticals presently has a consensus price target of $8.24, indicating a potential upside of 255.36%. uniQure has a consensus price target of $40.00, indicating a potential upside of 211.53%. Given Zentalis Pharmaceuticals' higher probable upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than uniQure.
uniQure received 595 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 70.66% of users gave uniQure an outperform vote while only 61.86% of users gave Zentalis Pharmaceuticals an outperform vote.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Zentalis Pharmaceuticals' return on equity of -43.91% beat uniQure's return on equity.
Summary
Zentalis Pharmaceuticals and uniQure tied by winning 9 of the 18 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ZNTL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ZNTL Stock Alerts